Stock Price Quote

VENUS REMEDIES LTD.

NSE : VENUSREMBSE : 526953ISIN CODE : INE411B01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE736.0014.6 (+2.02 %)
PREV CLOSE ( ) 721.40
OPEN PRICE ( ) 692.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 648
TODAY'S LOW / HIGH ( )687.05 740.00
52 WK LOW / HIGH ( )272.2 848.9
NSE729.152.9 (+0.4 %)
PREV CLOSE( ) 726.25
OPEN PRICE ( ) 710.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 18061
TODAY'S LOW / HIGH( ) 690.00 740.00
52 WK LOW / HIGH ( )270.25 839.9
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1989
Management Info
Pawan Chaudhary - Chairman Pawan Chaudhary - Managing Director
Registered Office

Address S. C. O. 857, C. No. 10,2nd Floor,N A C Manimajra,
Chandigarh,
Union Territory-160101

Phone 0172-2561244/5577

Email info@venusremedies.com

Website www.venusremedies.com / www.vmrcindia.com

Registrars Details
MUFG Intime India Pvt Ltd.
Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi
Listing : BSE, NSE

NEWS

19Jan Venus Remedies informs about board mee
Venus Remedies has informed that the meeting of Board of Directors is sc..
09Jan Venus Remedies gets marketing authoriz
Venus Remedies has received marketing authorisation in Indonesia for its..
09Jan Venus Remedies soars on getting market
Venus Remedies is currently trading at Rs. 727.00, up by 15.75 points or..
08Dec Venus Remedies informs about press rel
Venus Remedies has informed about press release titled - 'Venus Remedies..
01Dec Venus Remedies informs about update o
Venus Remedies has informed that the company has concluded all pending I..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit192.4525.5
Gross Profit 256 790.6
Operating Profit 315.2907.7
Net Sales 1926.56394.6

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  27604.70 (1.43%)
M.Cap ( in Cr)58658.06
Senores Pharmaceutic (BSE)
peergroup  834.80 (6.60%)
M.Cap ( in Cr)3844.55
Aarti Pharmalabs (BSE)
peergroup  794.40 (5.55%)
M.Cap ( in Cr)7201.02
Sanofi Cons. Health (BSE)
peergroup  4084.90 (0.97%)
M.Cap ( in Cr)9407.78
Ajanta Pharma (BSE)
peergroup  2714.30 (1.13%)
M.Cap ( in Cr)33911.28

Shareholding Pattern

NON-INSTITUTION 54.96%
PROMOTERS 41.76%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Venus Remedies Ltd.

Venus Remedies Ltd. was incorporated in the year 1989. Its today's share price is 736. Its current market capitalisation stands at Rs 983.81 Cr. In the latest quarter, company has reported Gross Sales of Rs. 6394.64 Cr and Total Income of Rs.6602.43 Cr. The company's management includes Neha, Anil Kumar, Jagdish Chander Sharma, NPS Monga, Savita Gupta, Navdeep Sud, Akshansh Chaudhary, Ashutosh Jain, Peeyush Jain, Manu Chaudhary, Pawan Chaudhary, Pawan Chaudhary.

It is listed on the BSE with a BSE Code of 526953 , NSE with an NSE Symbol of VENUSREM and ISIN of INE411B01019. It's Registered office is at S. C. O. 857, C. No. 10,2nd Floor,N A C ManimajraChandigarh-160101, Union Territory. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are JK Jain & Associates, Prem Garg & Associates, Vinod Kumar & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.